Your session is about to expire
← Back to Search
Corneal Collagen Crosslinking for Keratoconus
Study Summary
This trial found that the accelerated crosslinking method was effective in reducing the progression of keratoconus.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 or older with a diagnosis of keratoconus or corneal ectasia.My eye condition is related to keratoconus or corneal ectasia after surgery.I have removed my contact lenses for a week before my eye test.I can attend all scheduled follow-up visits.I have noticeable scarring in the treated eye area.I do not have any conditions like nystagmus that would prevent me from keeping my gaze steady during treatments.I can attend all scheduled follow-up visits.You have a central or inferior steepening on the Pentacam map.I am 18 or older with a diagnosis of keratoconus or corneal ectasia.I can remove my contact lenses for a week before the eye test.You have an allergy or sensitivity to the study drugs.You have a condition that could make it difficult for your skin to heal properly.I have had a chemical injury or slow healing in my eye.I have had eye conditions that could cause future issues, excluding vision correction needs.My eye condition is related to keratoconus or corneal ectasia after surgery.
- Group 1: Continuous UVA
- Group 2: Pulsed UVA
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people will be given this medication as part of the research?
"That is correct, the information available on clinicaltrials.gov indicates that the trial is currently underway and looking for 170 individuals from 1 locations."
Are new patients needed for this ongoing research project?
"The clinicaltrials.gov website indicates that the trial is still looking for subjects. According to the site, the 170 patients are needed at a single location. The trial was posted on 7/30/2021 and was last updated 9/15/2021."
For what conditions is Pulsed UVA therapy most often the first line of treatment?
"Pulsed UVA is an effective treatment for dietary and nutritional therapies, vitamin deficiency, and joint pain."
Has the FDA cleared Pulsed UVA for public use?
"There is some evidence to support Pulsed UVA's efficacy, as this is a Phase 3 trial. Furthermore, there is enough safety data from multiple rounds of testing to give it a safety score of 3."
What are some other examples of research that has been done using Pulsed UVA?
"Pulsed UVA is being trialed in 20 different studies at the moment, 11 of which are in the 3rd stage of clinical trials. The majority of research centres for Pulsed UVA are located in San Francisco, but there are a total of 47 sites running these tests."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Typically responds via
Share this study with friends
Copy Link
Messenger